Quick Answer
Moderna, Inc. reported Net Income Loss of -$2.82 billion for the year ending 2025.
- Moderna, Inc. showed an increase of +20.8% in Net Income Loss from 2024 to 2025.
- This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$72.38 million | Q2 2018: -$90.60 million | Q3 2018: -$80.33 million | Q1 2019: -$132.58 million | Q2 2019: -$134.94 million | Q3 2019: -$123.22 million | Q1 2020: -$124.00 million | Q2 2020: -$117.00 million | Q3 2020: -$233.00 million | Q1 2021: $1.22 billion | Q2 2021: $2.78 billion | Q3 2021: $3.33 billion | Q1 2022: $3.66 billion | Q2 2022: $2.20 billion | Q3 2022: $1.04 billion | Q1 2023: $79.00 million | Q2 2023: -$1.38 billion | Q3 2023: -$3.63 billion | Q1 2024: -$1.18 billion | Q2 2024: -$1.28 billion | Q3 2024: $13.00 million | Q1 2025: -$971.00 million | Q2 2025: -$825.00 million | Q3 2025: -$200.00 million.
- Over the full 10 years of available data (2016 to 2025), Moderna, Inc.'s Net Income Loss has declined by 1,205.2%.
- Historical annual values: Fiscal year 2025: -$2.82 billion | Fiscal year 2024: -$3.56 billion | Fiscal year 2023: -$4.71 billion | Fiscal year 2022: $8.36 billion | Fiscal year 2021: $12.20 billion | Fiscal year 2020: -$747.00 million | Fiscal year 2019: -$514.00 million | Fiscal year 2018: -$384.73 million | Fiscal year 2017: -$255.92 million | Fiscal year 2016: -$216.21 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: